A Historic Breakthrough in Psoriasis Treatment: The First Oral IL-23 Peptide Icotrokinra Approved, Ushering in the Era of “Oral Biologics”

Amid the ongoing shift toward precision and convenience in the treatment of immune-mediated diseases, psoriasis has reached a landmark moment. In March 2026, the U.S. Food and Drug Administration (FDA) approved the world’s first oral IL-23 receptor antagonist peptide, Icotrokinra (brand name: Icotyde), for the systemic treatment of patients with moderate-to-severe plaque psoriasis. This milestone not only represents the arrival of a new therapeutic option but also signals the official transition of psoriasis treatment into the era of “oral biologics.”

From the “Injection Era” to the “Oral Era”

Over the past decade, with the IL-23/IL-17 axis established as a central pathogenic pathway in psoriasis, biologics—especially IL-23 monoclonal antibodies—have dramatically improved skin clearance rates and patient quality of life. However, these therapies rely on subcutaneous or intravenous administration, which can limit long-term adherence and pose challenges related to convenience and cold-chain logistics.

In contrast, traditional oral small-molecule therapies (such as certain JAK or TYK2 inhibitors) offer ease of administration but may fall short in target selectivity and long-term safety, making them difficult to fully replace biologics.

Against this backdrop, Icotrokinra represents a major technological breakthrough. Designed as a macrocyclic peptide, it combines biologic-level target specificity with oral bioavailability—achieving, for the first time, both high efficacy and convenience in a single therapeutic modality.

Precision Mechanism: Targeting the Core of the IL-23 Pathway

Icotrokinra acts by selectively targeting the IL-23 receptor (IL-23R). IL-23 is a key cytokine driving the differentiation of Th17 cells and amplifying inflammatory responses, with downstream effects that promote keratinocyte hyperproliferation and chronic inflammation.

By blocking the interaction between IL-23 and its receptor, Icotrokinra inhibits the inflammatory cascade at its source, thereby controlling skin lesions and alleviating symptoms. This “upstream precision blockade” enables a balance between deep efficacy and favorable safety.

Notably, unlike monoclonal antibodies, the peptide-based structure retains high binding affinity while offering more flexible pharmacokinetics—an essential factor enabling its oral administration.

Clinical Performance: Efficacy Meets Speed

Clinical data reported to date highlight the strong performance of Icotrokinra across multiple endpoints.

In terms of onset, some patients experienced noticeable improvement as early as two weeks after treatment initiation—an important advancement compared to many biologics with slower onset.

Regarding efficacy, approximately 70% of patients achieved clear or almost clear skin (PASI90) at Week 16. In longer-term follow-up, nearly half of patients reached complete skin clearance (PASI100), approaching or even matching outcomes seen with established IL-23 monoclonal antibodies.

Durability has also been demonstrated. Over a 52-week period, most patients maintained stable skin clearance without significant loss of efficacy, indicating strong long-term disease control.

Importantly, Icotrokinra has also shown favorable efficacy and tolerability in adolescent populations, further expanding its potential clinical applicability.

Safety and Adherence: Key Advantages for Long-Term Management

From a safety perspective, the overall incidence of adverse events with Icotrokinra is comparable to placebo, with no new major safety signals observed. This is particularly critical for a chronic disease requiring long-term or lifelong management.

Its advantage in adherence is even more pronounced. With a once-daily oral regimen, Icotrokinra significantly lowers the barrier to treatment, eliminating the discomfort and psychological burden associated with injections, as well as the need for cold storage and clinical administration settings.

For patients in real-world settings, this “treatment without burden” may be as meaningful as improvements in efficacy.

Clinical and Market Impact: Reshaping the Treatment Landscape

The approval of Icotrokinra not only provides a new therapeutic option but also has the potential to reshape the overall treatment paradigm for psoriasis.

On one hand, it may emerge as a first-line systemic therapy, particularly for patients who are reluctant to use injectable treatments or struggle with adherence. On the other hand, its combination of oral administration and high selectivity positions it as a direct competitor to existing IL-23 monoclonal antibodies.

From a broader perspective, this innovation carries platform-level significance. As the first successfully commercialized oral peptide immunomodulator, its underlying technology may extend to other IL-23–related diseases, including psoriatic arthritis and inflammatory bowel disease, opening new avenues for the treatment of chronic immune disorders.

Conclusion

Looking back at the evolution of psoriasis treatment—from traditional immunosuppressants to biologics and now to targeted oral peptide therapies—each step has brought the field closer to the ideal of high efficacy, safety, and convenience.

The emergence of Icotrokinra marks a pivotal point in this journey. It not only overcomes the long-standing limitation that biologics must be injectable but also redefines the potential of oral therapies.

As similar technologies continue to advance, the future of immunotherapy is likely to move beyond trade-offs in administration methods and toward truly patient-centered precision medicine.

For psoriasis, this is not merely the launch of a new drug—it is the beginning of an entirely new therapeutic era.

Against the backdrop of continuous breakthroughs in global drug innovation, cutting-edge therapies like Icotrokinra are rapidly advancing from research to clinical application and market access. As a key bridge connecting global innovative drug resources with clinical needs, DengYue Medicine will continue to monitor frontier developments in immune therapies, including the IL-23 pathway, and remain committed to improving the accessibility and clinical value of innovative treatments.